Vicore Pharma Holding AB
STO:VICO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.9665
23.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vicore Pharma Holding AB
Vicore Pharma Holding AB
Net Income (Common)
Vicore Pharma Holding AB
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vicore Pharma Holding AB
STO:VICO
|
Net Income (Common)
-kr200.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Net Income (Common)
kr365.4m
|
CAGR 3-Years
27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Net Income (Common)
kr90.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Net Income (Common)
-kr3.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Net Income (Common)
kr3.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
BioArctic AB
STO:BIOA B
|
Net Income (Common)
kr229.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Vicore Pharma Holding AB
Glance View
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.
See Also
What is Vicore Pharma Holding AB's Net Income (Common)?
Net Income (Common)
-200.1m
SEK
Based on the financial report for Jun 30, 2024, Vicore Pharma Holding AB's Net Income (Common) amounts to -200.1m SEK.
What is Vicore Pharma Holding AB's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-20%
Over the last year, the Net Income (Common) growth was 24%. The average annual Net Income (Common) growth rates for Vicore Pharma Holding AB have been 2% over the past three years , -20% over the past five years .
You don't have any saved screeners yet
